Multidisciplinary Care Teams to Reduce Major Amputations for Patients
Background. Approximately 2 million Americans develop a diabetic foot ulcer (DFU) annually; >50% die and 5% lose a limb within 5 years. IDSA guidelines recommend multidisciplinary team care for these patients (moderate evidence). Little is known about who should compose the team or how the team should function (low evidence). We conducted a systematic review following PRISMA guidelines to evaluate the effect of multidisciplinary team care on major amputation in patients with DFU's and describe team composition and function.
Methods. A medical reference librarian searched databases without date limits through May 26, 2017. Two independent reviewers screened abstracts and then full text using the following inclusion criteria: original article; reported the effect of multidisciplinary teams (≥2 specialties) on major amputation; included a control group; >50% of study patients had diabetes; in English. Abstracted data included study design, patient characteristics, team composition and function, and major amputation rates.
Results. We included 33 studies ( Figure 1 ). Five (15%) were in the United States, and 27 (82%) were historically controlled trials. Thirty-two (97%) documented lower major amputation rates among patients cared for by a multidisciplinary team ( Figure 2 ). Relative reductions ranged from 11 to 90%. A 12% relative increase was observed in the single study documenting increased rates of major amputation following multidisciplinary care. Thirty-six different specialties were represented in the 26 studies reporting team composition, including: endocrinology (85%), vascular surgery (73%), orthopedic surgery (65%), podiatry (54%), and infectious disease (50%). Teams functioned in the following settings: inpatient (30%), outpatient (15%), or both (55%). Among 12 studies reporting team function, the following topics were addressed: surgical debridement/offloading (66%), vascular disease (63%), infection (59%), and glycemic control (41%).
Conclusion. Care by multidisciplinary teams may help prevent major amputation for patients with DFUs. Team composition and function, and reductions in major amputation rates, varied considerably. Research directly comparing different models of multidisciplinary care is needed.
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No reported disclosures. Background. Delafloxacin (DLX) is a broad-spectrum fluoroquinolone (FQ) antibacterial; approved in 2017 by the Food and Drug Administration for treatment of acute bacterial skin and skin structure infections (ABSSSIs). DLX is in clinical development for community-acquired bacterial pneumonia (CABP). In this study, in vitro susceptibility (S) for DLX and comparator agents for Gram-negative (GN) and Gram-positive (GP) anaerobic isolates from Phase 3 ABSSSI clinical trials were determined and compared with the microbiologic response for evaluable isolates.
Evaluation of Delafloxacin
Methods. A total of 84 anaerobic isolates were collected during Phase 3 ABSSSI clinical trials and 9 additional Bacteroides fragilis (BF) were collected as part of the 2017 SENTRY surveillance program. The isolates tested included 11 BF, 13 Clostridium perfringens (CP), and other species with <10 isolates (table). Isolate identifications were confirmed by molecular methods. Susceptibility testing was performed according to CLSI agar dilution methodology (M11, 2012). Other antimicrobials tested included clindamycin (CD), metronidazole (MTZ), and moxifloxacin (MXF). In addition, the activity of DLX and MXF were compared at standard pH 7.0 and at pH 6.0.
Results. DLX had the lowest MIC 50/90 values against both GP and GN species and was 32-fold more active than MXF for all organisms. For BF, DLX was 4-to 16-fold more active than the other comparators. For CP, DLX was 32-to 64-fold more active than the 3 comparators. When comparing the activity of DLX and MXF at pH 6 vs. pH 7, DLX had the same MIC 50/90 values while MXF MIC 50/90 values were 2-fold less active at the lower pH (Table 1) . Of the 84 clinical trial isolates, 21 were recovered from subjects in the microbiologically evaluable at follow-up (MEFU) population. All of the subjects had a favorable microbiological response (presumed eradication) at FU.
Conclusion. DLX demonstrated potent in vitro antibacterial activity against anaerobic isolates tested, including BF and CP and was more active than MXF. For all isolates combined, DLX activity was unchanged at lower pH while MXF MIC values increased 2-fold. These data suggest that DLX activity remains potent at a lower pH common at sites of infection. 
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